Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione del Piemonte per l'Oncologia
Age
18–78
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical and pathological confirmation of peritoneal carcinomatosis from gastric, colorectal and ovarian cancers or primary peritoneal tumors.
Patients aged between 18 and 78 years.
Performance status sec. ECOG ≤ 2
Disease progression/relapse after at least one line of previous i.v. standard chemotherapy in gastric cancer and primary peritoneal tumors and two lines in colorectal and ovarian cancers.
You may not be if
Blood and electrolyte counts, liver, renal and cardiopulmonary function parameters within 10% of the normal range.
Written informed consent.
Tumor mass present on CT-scan in order to allow tumor response assessment with RECIST-criteria.
Extra-abdominal metastatic disease, with the exception of isolated pleural carcinomatosis.
Bowel obstruction.
Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias.
Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system.
Creatinine clearance \< 60 ml /min.
Pregnancy.
Previous treatment reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenediones.
Known allergy to cisplatin or other platinum-containing compounds or to doxorubicin.
Patients of both sexes who do not conduct complete abstinence from heterosexual relationships or agree to use an effective clinically acceptable method (with failure rate \<1%) during the study and the following 6 months after the last treatment.